A cost utility analysis of CYP2D6 pharmacogenetic guided dosing versus standard dosing of risperidone for treatment of schizophrenia
May 1, 2014, 00:00
10.1016/j.jval.2014.03.1271
https://www.valueinhealthjournal.com/article/S1098-3015(14)01322-9/fulltext
Title :
A cost utility analysis of CYP2D6 pharmacogenetic guided dosing versus standard dosing of risperidone for treatment of schizophrenia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)01322-9&doi=10.1016/j.jval.2014.03.1271
First page :
A217
Section Title :
Mental Health
Open access? :
No
Section Order :
732